THERAPY DOSSIER · th-32a6c045ca63

Exherin (ADH-1), an N-cadherin-blocking synthetic peptide; plus AAV6-Cre and AAV6-CRISPR/Cas9 guide RNA for local N-cadherin (Cdh2) ablation

Drug · N-cadherin (CDH2) antagonist; cyclic pentapeptide vascular-targeting agent (ChEMBL has no explicit mechanism record). Combination also includes AAV6-Cre and CRISPR/Cas9 for Cdh2 ablation.

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: N-cadherin (CDH2) antagonist; cyclic pentapeptide vascular-targeting agent (ChEMBL has no explicit mechanism record). Combination also includes AAV6-Cre and CRISPR/Cas9 for Cdh2 ablation.
Target: N-cadherin (CDH2)
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL3818130 ↗
ChEMBL max phase: 1 / 4 (development scale, not regulatory approval)
Synonyms: Exherin; ADH-1; Cys-His-Ala-Val-Cys; NSC-729477
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00264433 ↗PHASE2completed

Phase 2a ADH-1 Single Agent in N-Cadherin Positive Advanced/Recurrent Solid Tumors

Neoplasms

Enrolment not recorded · Results not recorded

NCT00265057 ↗PHASE1/PHASE2completed

Exherin (ADH-1) Once Weekly IV in N-Cadherin Expressing Incurable Solid Tumors

Neoplasms

Enrolment not recorded · Results not recorded

NCT00421811 ↗PHASE1/PHASE2completed

Phase 1/2 Systemic ADH-1 + Isolated Limb Infusion Melphalan in In-Transit Melanoma

Neoplasms

Enrolment: 56 · Results not recorded

NCT00225550 ↗PHASE1/PHASE2terminated

Phase 1/2 Exherin (ADH-1) Daily x5 IV in N-Cadherin Expressing Solid Tumors

Neoplasms

Enrolment not recorded · Results not recorded

NCT01825603 ↗PHASE1completed

Phase I ADH-1 + Gemcitabine/Cisplatin in Pancreatic/Biliary Cancers

Metastatic Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma

Enrolment: 17 · Results not recorded

NCT00390676 ↗PHASE1completed

Phase 1 ADH-1 + Carboplatin/Docetaxel/Capecitabine in N-Cadherin+ Solid Tumors

Neoplasms

Enrolment not recorded · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 33159076 ↗2020Reported benefit

Injury triggers fascia fibroblast collective cell migration to drive scar formation through N-cadherin.

MouseWoundC57BL/6J plus fibroblast lineage reporter and conditional lines including En1-Cre and Wnt1-Cre crossed to dual fluorescence membrane and nuclear reporters, N-cadherin (Cdh2) floxed mice and Cas9 knock-in miceBoth male and female mice; human donors of both sexesAddition to explant culture medium for Exherin; subcutaneous injection into the fascia surrounding wounds for AAV6 vectorsExherin 500 microgram/mL in explant culture medium; AAV6 vi…Exherin present in the medium from the start of explant culture, that is from t…

Model: Full-thickness excisional skin wounds through the panniculus carnosus and fascia (2 mm, 3 mm and 5 mm biopsy punches, some splinted with silicone rings), intravital imaging through a dorsal skinfold chamber, and ex vivo full-thickness skin-fascia explants (scar-like tissue in a dish, SCAD) from back skin, buccal mucosa and human skin

Injury triggered N-cadherin upregulation and swarming collective migration of Engrailed-1 lineage fascia fibroblasts towards the wound centre, a behaviour absent from oral mucosa fibroblasts. Exherin prevented fibroblast aggregation and skin contraction, abolished wound-induced alpha-SMA upregulati…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…